Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Cancer Metastatic × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 84 Carcinoma, Renal Cell 60 Neoplasm Metastasis 38 Neoplasms 32 Neuroendocrine Tumors 29 Kidney Neoplasms 24 Recurrence 16 Carcinoma, Non-Small-Cell Lung 16 Tuberous Sclerosis 14 Prostatic Neoplasms 14 Triple Negative Breast Neoplasms 13 Head and Neck Neoplasms 12 Glioblastoma 12 Pancreatic Neoplasms 11 Lymphoma, Mantle-Cell 11 Lymphoma 11 Carcinoma, Hepatocellular 11 Brain Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 10 Leukemia, Lymphocytic, Chronic, B-Cell 10 Hodgkin Disease 10 Colorectal Neoplasms 10 Carcinoma, Neuroendocrine 10 Sarcoma 9 Precursor Cell Lymphoblastic Leukemia-Lymphoma 9 Glioma 9 Waldenstrom Macroglobulinemia 8 Lymphoma, Follicular 8 Lung Neoplasms 8 Carcinoid Tumor 8

Interventions

Fulvestrant 5 Letrozole 4 exemestane 3 Anastrozole 3 ribociclib 2 dalpiciclib 2 apatinib 2 Gemcitabine 2 Capecitabine 2 tusamitamab ravtansine 1 trastuzumab deruxtecan 1 pyrotinib 1 patritumab deruxtecan 1 palbociclib 1 olaparib 1 nirogacestat 1 margetuximab 1 irinotecan sucrosofate 1 fluzoparib 1 abemaciclib 1 Zoledronic Acid 1 Vinorelbine 1 Trastuzumab 1 Tamoxifen 1 Paclitaxel 1 Neoadjuvant Therapy 1 Liposomes 1 Irinotecan 1 Ga(III)-DOTATOC 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02511639 2020-12-03

MAIN-A

Istituto Oncologico Veneto IRCCS

Phase 3 Completed

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡